Increased extracellular local levels of estradiol in normal breast in vivo during the luteal phase of the menstrual cycle.
Reads0
Chats0
TLDR
The results in this study suggest that progesterone may be one regulator in the local conversion of estrogen precursors into potent estradiol in normal breast tissue.Abstract:
Estrogen exposure is a major risk factor for breast cancer. Tissue estrogen originates from the ovaries but a significant portion is also produced by enzyme activity locally in the breast itself. How these enzymes are regulated is not fully understood. The extracellular space, where the metabolic exchange and cell interactions take place, reflects the environment that surrounds the epithelium but there has been no previous study of hormone concentrations in this compartment. In the present study microdialysis was used to measure extracellular estrogen concentrations in breast tissue and abdominal subcutaneous fat in 12 healthy women in vivo. It was found that women with high plasma progesterone levels had significant increased levels of estradiol in breast tissue compared with fat tissue (breast tissue 168+/-6 pM; subcutaneous fat, 154+/-5 pM; P<0.05), whereas women with low plasma progesterone exhibited no difference. Moreover, there was a significant correlation between local breast tissue estradiol and plasma progesterone levels (r=0.709, P<0.01). There was no difference in estrone sulphate in breast and fat tissue regardless of progesterone levels. Estrone was not detectable. The results in this study suggest that progesterone may be one regulator in the local conversion of estrogen precursors into potent estradiol in normal breast tissue.read more
Citations
More filters
Journal ArticleDOI
CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer
Susanne Svensson,Annelie Abrahamsson,Gabriela Vazquez Rodriguez,Anna-Karin Olsson,Lasse Jensen,Lasse Jensen,Yihai Cao,Yihai Cao,Yihai Cao,Charlotta Dabrosin +9 more
TL;DR: New light is shed on the mechanisms underlying the progression of ER+ breast cancer and the potential of novel therapies targeting CCL2 and CCL5 pathways is indicated.
Journal ArticleDOI
Estrogens in the breast tissue: a systematic review
TL;DR: A systematic review summarizes published studies that measured local estrogen levels in the breast and offers suggestions for strategies to fill gaps in existing scientific knowledge.
The Selective Estrogen Enzyme Modulators (SEEM) in breast cancer
J. R. Pasqualini,G. S. Chetrite +1 more
TL;DR: In this article, the concept d'intracrinologie aux tissus cancereux du sein, c'est-a-dire que l'hormone produit son effet biologique dans l'organe qui la synthetise, car il a ete demontre que les progestines peuvent avoir un effet inhibiteur, stimulant, or etre sans effet sur la proliferation cellulaire.
Journal ArticleDOI
Disposition of hop prenylflavonoids in human breast tissue
Selin Bolca,Jinghu Li,Dejan Nikolic,Nathalie Roche,Phillip Blondeel,Sam Possemiers,Denis De Keukeleire,Marc Bracke,Arne Heyerick,Richard B. van Breemen,Herman Depypere +10 more
TL;DR: Low doses of prenylflavonoids are unlikely to elicit estrogenic responses in breast tissue, and their derived E(2)-equivalents were negligible compared with E( 2) in adipose and glandular tissue.
Journal ArticleDOI
In vivo measurement of tumor estradiol and Vascular Endothelial Growth Factor in breast cancer patients
Stina Garvin,Charlotta Dabrosin +1 more
TL;DR: It is concluded that VEGF and estradiol correlates significantly in normal breast tissue and microdialysis may be used to provide novel insight in breast tumor biology and the regulation of molecules in the extracellular space of human breast tumors in vivo.
References
More filters
Journal ArticleDOI
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
Jacques E. Rossouw,Garnet L. Anderson,Ross L. Prentice,Andrea Z. LaCroix,Charles Kooperberg,Marcia L. Stefanick,Rebecca D. Jackson,Shirley A.A. Beresford,Barbara V. Howard,Karen C. Johnson,Jane Morley Kotchen,Judith K. Ockene +11 more
TL;DR: Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
Journal ArticleDOI
Breast cancer and hormone-replacement therapy in the Million Women Study.
TL;DR: Current use of HRT is associated with an increased risk of incident and fatal breast cancer; the effect is substantially greater for oestrogen-progestagen combinations than for other types of H RT.
Journal ArticleDOI
Breast cancer and hormone-replacement therapy: the Million Women Study.
TL;DR: A successful user bias is suggested, although the same effect might be seen if HRT accelerates rather than initiates breast-cancer growth, and women will increasingly be deprived of an effective remedy for unpleasant climacteric symptoms and osteoporosis.
Journal ArticleDOI
Microdialysis--principles and applications for studies in animals and man.
TL;DR: The technique has been extensively used in the neurosciences to monitor neurotransmitter release, and is now finding application in monitoring of the chemistry of peripheral tissues in both animal and human studies.
Journal ArticleDOI
Is estradiol a genotoxic mutagenic carcinogen
TL;DR: Data suggest that E2 is a weak carcinogen and weak mutagen capable of inducing genetic lesions with low frequency and may develop by hormone receptor-mediated proliferation of such damaged cells.
Related Papers (5)
Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo
In vivo measurement of tumor estradiol and Vascular Endothelial Growth Factor in breast cancer patients
Stina Garvin,Charlotta Dabrosin +1 more